Multi-omics analysis reveals mechanism of action for ruthenium-based anti-cancer agent

This study is led by Prof. Cai-Ping Tan, Prof. Zong-Wan Mao (MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University) and Prof. Zheng-Qiu Li (School of Pharmacy, MOE Key Laboratory of Tumor Molecular Biology, Jinan University).

Airway disease drug from Insmed succeeds in one of the year’s most anticipated trials

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the

May 28, 2024

Groundbreaking project seeks to illuminate the complexities of Parkinson’s

Launching today, Landmark is a groundbreaking three-year research programme that aims to understand Parkinson’s in unprecedented detail. The project brings together Parkinson’s UK, Imperial College

September 24, 2024

FDA adcomm votes unanimously in favor of full approval for Eisai’s new Alzheimer’s drug

The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee on Friday voted 6-0 in favor of fully approving Eisai and Biogen’s Alzheimer’s drug Leqembi

June 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.